Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Immatics N.V is a biotechnology business based in the US. Immatics N-V shares (IMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Immatics N-V employs 320 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$14.64|
|52-week range||$8.75 - $16.30|
|50-day moving average||$12.57|
|200-day moving average||$11.97|
|Wall St. target price||$24.30|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.61|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-10)||-1.08%|
|1 month (2021-08-19)||25.24%|
|3 months (2021-06-18)||24.07%|
|6 months (2021-03-19)||3.17%|
|1 year (2020-09-18)||59.30%|
|2 years (2019-09-15)||N/A|
|3 years (2018-09-15)||N/A|
|5 years (2016-09-15)||N/A|
|Revenue TTM||$29.9 million|
|Gross profit TTM||$-35,832,000|
|Return on assets TTM||-33.16%|
|Return on equity TTM||-5802.34%|
|Market capitalisation||$931.1 million|
TTM: trailing 12 months
There are currently 2.1 million Immatics N-V shares held short by investors – that's known as Immatics N-V's "short interest". This figure is 1.3% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Immatics N-V shares can be evaluated.
Immatics N-V's "short interest ratio" (SIR) is the quantity of Immatics N-V shares currently shorted divided by the average quantity of Immatics N-V shares traded daily (recently around 105779.75522693). Immatics N-V's SIR currently stands at 19.61. In other words for every 100,000 Immatics N-V shares traded daily on the market, roughly 19610 shares are currently held short.
However Immatics N-V's short interest can also be evaluated against the total number of Immatics N-V shares, or, against the total number of tradable Immatics N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immatics N-V's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Immatics N-V shares in existence, roughly 30 shares are currently held short) or 0.0723% of the tradable shares (for every 100,000 tradable Immatics N-V shares, roughly 72 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Immatics N-V.
Find out more about how you can short Immatics N-V stock.
We're not expecting Immatics N-V to pay a dividend over the next 12 months.
Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Bytecoin (BCN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the IRON Titanium Token (TITAN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Sapchain (SAP) token as well as a list of exchanges you can trade it on.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 10, 2021
This guide will show you step-by-step instructions on how to buy the Star Atlas DAO (POLIS) token as well as a list of exchanges you can trade it on.
Everything we know about the Sunshine Biopharma IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the TDCX IPO, plus information on how to buy in.
Everything we know about the First Watch Restaurant Group IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.